First Trust Direct Indexing L.P. Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

First Trust Direct Indexing L.P. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 19.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 10,825 shares of the medical research company’s stock after buying an additional 1,798 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in IQVIA were worth $2,565,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. First Foundation Advisors grew its holdings in shares of IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares in the last quarter. Team Hewins LLC grew its stake in IQVIA by 5.0% in the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after purchasing an additional 46 shares during the period. Invera Wealth Advisors LLC raised its stake in shares of IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares during the period. Covestor Ltd boosted its holdings in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after buying an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after buying an additional 48 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 0.1 %

IQV opened at $216.04 on Thursday. The firm has a market capitalization of $39.38 billion, a P/E ratio of 28.06, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a fifty day moving average price of $235.88 and a 200-day moving average price of $230.06. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IQV. Robert W. Baird boosted their target price on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research note on Friday, September 20th. Evercore ISI reduced their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Royal Bank of Canada began coverage on IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price on the stock. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.27.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.